Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target.
about
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque developmentClinical usefulness of novel serum and imaging biomarkers in risk stratification of patients with stable anginaAntioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a reviewThe role of lipoprotein-associated phospholipase A2 in a murine model of experimental autoimmune uveoretinitisLp-PLA2 Antagonizes Left Ventricular Healing After Myocardial Infarction by Impairing the Appearance of Reparative MacrophagesMetabolomic profile of hepatitis C virus-infected hepatocytesEffect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trialCollaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literatureThe inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.Lp-PLA2 Inhibition-The Atherosclerosis Panacea?Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease.Markers of inflammation and cardiovascular disease in recently diagnosed celiac disease patientsLipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study.Lipoprotein-associated phospholipase-A2 activity and its diagnostic potential in patients with acute coronary syndrome and acute ischemic stroke.Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles.Bioactive products generated by group V sPLA(2) hydrolysis of LDL activate macrophages to secrete pro-inflammatory cytokines.Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetesLipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic miceBiomarkers and cardiovascular risk assessment for primary prevention: an update.Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D.Lyso-phosphatidylcholine induces osteogenic gene expression and phenotype in vascular smooth muscle cells.Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.Vascular effects of the red blood cell storage lesionAcyl chain-dependent effect of lysophosphatidylcholine on endothelial prostacyclin productionCirculating and PBMC Lp-PLA2 associate differently with oxidative stress and subclinical inflammation in nonobese women (menopausal status).Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.Lipoprotein-associated phospholipase A₂ is related to plaque stability and is a potential biomarker for acute coronary syndrome.Taiwanese female vegetarians have lower lipoprotein-associated phospholipase A2 compared with omnivores.Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women.Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk.Lipoprotein-associated phospholipase A₂ activity predicts progression of subclinical coronary atherosclerosisMass spectrometry and inflammation--MS methods to study oxidation and enzyme-induced changes of phospholipids.Uremia alters HDL composition and functionSTABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.Association of lipoprotein-associated phospholipase A₂ with characteristics of vulnerable coronary atherosclerotic plaques.Ambient air pollution and lipoprotein-associated phospholipase A₂ in survivors of myocardial infarctionKidney function decline in the elderly: impact of lipoprotein-associated phospholipase A(2).Genotype x adiposity interaction linkage analyses reveal a locus on chromosome 1 for lipoprotein-associated phospholipase A2, a marker of inflammation and oxidative stress
P2860
Q24634492-BB44A329-77E1-4E6D-A5E6-953308AA0070Q26859111-097FF127-446C-4D04-AB34-83860AC6B72DQ26991853-876D329E-B2D6-41EC-833F-EBC906C4FA2AQ27310393-16D1B0E3-1DD6-4EA2-A4C0-2E3FAE9F3D20Q28388609-E39D964B-3559-4B2B-9A5C-7781079600F4Q28476531-4328F828-65A2-4D33-95CD-21CCAC69DBD5Q28539991-F9F9A0E2-57F1-48CA-B4F6-2C9BFF277A46Q31100823-F8CFB36C-D2A3-4DEC-A59C-2698473A6716Q33536648-1758FDD9-9001-42EB-AFF3-5BD650BAB991Q33566165-0E45C62F-85A2-45E2-96FA-E93E1B3F10D2Q33664272-979A2024-C1E3-4623-B0FA-DAB9531F6F32Q33666216-766D28FE-7A36-4D7A-B872-BA6E8540D059Q33721199-A88323C0-2D44-460A-B6F8-D603CBDF9E21Q33755952-C531955D-55EA-4E11-8B88-B8AEE4BF09AEQ33764961-92DF55F3-C8D0-40D7-B1E0-0C465BEBBD8DQ33768940-8265C461-5DAA-4F5A-A7BE-7CAA42BCAB9CQ33771533-2DFD1375-8CBC-42DB-A479-3B763B5993AAQ33803486-62C47A1B-760C-4154-9E87-16755BEFD04FQ33829154-0D553AEA-F40E-47FB-930D-6502D4221153Q33905765-A30D6732-52EF-4093-BE1F-135077048546Q33927398-949B536E-FA18-4876-88C3-019DE53F8A0DQ33945132-863E87E3-5B7F-4993-B748-52B728438DDBQ33987854-2548A6F1-3BF5-4B74-BC14-261E68336512Q34016317-2A66DF25-EA7F-481D-99E6-5C1DBBC75D19Q34029776-AA8C2FB8-553C-474C-899B-D71985CFFFC9Q34116412-41364E84-D007-46C6-9861-607C16331409Q34167997-B8EEAE0C-A538-4FF5-BC2D-DF2F2F53112EQ34214336-D58A1DBB-91BD-42DB-90A5-FC97682518F8Q34384281-11C511E9-774F-4A47-939B-69BACED90B69Q34474519-37CE7A42-A204-4D56-8B21-9E56EAD3F8DDQ34776755-7A5BC28C-B125-4AF0-8F44-35ABCBE34289Q34890672-D618C4F1-EF2A-4989-A6DF-F26C21E7A609Q35006841-6AD543D3-FEF2-47B8-B496-2C17E8485917Q35074231-F33D3355-8EA1-497E-AA7E-B82BAD58199DQ35210194-6760B8E1-FB29-4670-9BDF-E649AC71E555Q35217973-5A0F7A9A-67B0-423D-BBBF-3DD1B3012212Q35561851-7D83D97D-AFE5-4346-B0C8-7E7078732C60Q35570003-CD53150F-FA02-4A6E-B2C0-133565908EA5Q35576334-2CE34D97-2970-4212-924C-29B7AD5D68A8Q35616553-E9F3BA1D-EB60-4730-9B93-737CA4B2A966
P2860
Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Role of lipoprotein-associated ...... d possible therapeutic target.
@ast
Role of lipoprotein-associated ...... d possible therapeutic target.
@en
Role of lipoprotein-associated ...... d possible therapeutic target.
@nl
type
label
Role of lipoprotein-associated ...... d possible therapeutic target.
@ast
Role of lipoprotein-associated ...... d possible therapeutic target.
@en
Role of lipoprotein-associated ...... d possible therapeutic target.
@nl
prefLabel
Role of lipoprotein-associated ...... d possible therapeutic target.
@ast
Role of lipoprotein-associated ...... d possible therapeutic target.
@en
Role of lipoprotein-associated ...... d possible therapeutic target.
@nl
P921
P1476
Role of lipoprotein-associated ...... d possible therapeutic target.
@en
P2093
Andrew Zalewski
Colin Macphee
P304
P356
10.1161/01.ATV.0000160551.21962.A7
P407
P577
2005-02-24T00:00:00Z